Skip to content
PeptideGeek

Growth hormone

Tesamorelin, explained simply

The only FDA-approved peptide specifically designed to melt away stubborn belly fat by telling your brain to release more growth hormone naturally—working with your body's own systems rather than replacing them.

Well studied in peopleInjection under the skin (like insulin shots)16 cited sourcesResearch compound — not FDA approved

Start here

What is Tesamorelin?

Tesamorelin is an FDA-approved injectable peptide that works by telling your pituitary (the master hormone gland at the base of the brain) gland to release more of your body's own growth hormone rather than replacing it 910. It is best known for reducing visceral fat, the harmful deep belly fat wrapped around your organs 17, and it improves triglyceride and cholesterol levels as that fat decreases 12. Its FDA approval is for a use other than general weight loss, and it is given as an injection under the skin.

How it works in your body

Your pituitary (the master hormone gland at the base of the brain) gland (a pea-sized gland at the base of your brain) releases growth hormone throughout the day, especially while you sleep. As we age, this release decreases 13. Tesamorelin is basically a messenger molecule that tells your pituitary to release more growth hormone naturally 1. It's almost identical to the 44-amino-acid signal your hypothalamus (the brain region that runs your hormone system) already makes, but with a small chemical modification that makes it last longer in your body 6. When growth hormone goes up, it signals your body to break down fat for energy—especially the dangerous visceral fat wrapped around your organs 15. The beauty is that you're not injecting growth hormone itself; you're just amplifying your body's own system.

The deeper mechanism, for the curious

Tesamorelin is a lab-made analog (a modified version of a natural molecule) of human growth hormone-releasing hormone (GHRH, the brain signal that tells the pituitary (the master hormone gland at the base of the brain) to release growth hormone). It has 44 amino acids and a trans-3-hexenoic acid group added to the first amino acid, tyrosine 6. This change shields the molecule from being quickly broken down by dipeptidyl peptidase-4 (DPP-4, an enzyme that chops up peptides), so it lasts longer while still fitting its receptor fully 8. After an injection under the skin, tesamorelin attaches to GHRH receptors on somatotroph cells (growth-hormone-making cells) in the front of the pituitary gland. This activates adenylyl cyclase (an enzyme) through Gs-coupled signaling (a chain of internal messages) 9. That raises cAMP inside the cell (a chemical messenger), which prompts the growth hormone gene to turn on and growth hormone (GH) to be released in pulses 910. The extra GH makes the liver produce IGF-1 (a growth signal) and directly drives lipolysis (the breakdown of fat) in fat tissue, with a stronger effect on visceral fat (deep belly fat) 35. Visceral fat may respond more because visceral and subcutaneous (under the skin) fat (fat under the skin) differ in their GH receptors and fat-breaking enzymes 15. Unlike injected GH, tesamorelin keeps the body's normal feedback control through somatostatin (a hormone that holds GH back), which lowers the risk of GH staying too high for too long.

Evidence check

Well studied in people

This has been through large human trials — the strongest kind of evidence. Scientists have tested it on many people and measured what actually happened.

Every numbered marker on this page links to one of the 16 sources at the bottom.

96/100

Deep Belly (Visceral) Fat Reduction

FDA-approved with Phase 3 trial data showing 15-18% reduction in dangerous belly fat—among the strongest evidence for any fat-targeting peptide

89/100

Metabolic Health

Significantly improves triglycerides (blood fats), cholesterol ratios, and liver fat markers as visceral fat decreases

92/100

Natural Growth Hormone (GH) Boost

Increases IGF-1 levels by 100%+ while maintaining physiological feedback—works with your body's own systems

What the research points to

The most-asked question

How much Tesamorelin do I take?

The research-reported range is 2 mg, once daily.

  1. HIV visceral fat reduction

    2 mg (1.4 mg with Egrifta SV/WR F8 formulation)

    • How often
      Once daily
    • For how long
      26 weeks, continued long-term for sustained effect
    • How
      Injection under the skin

    FDA-approved dose for HIV-associated lipodystrophy (abnormal belly fat buildup); full dose from day one with no gradual build-up 6. The main phase 3 trials used 2 mg daily 1.

Adjusting your dose

You're at the right dose if…

Consider going up if…

  • You've been on the starting dose for 4+ weeks with no issues
  • IGF-1 (a growth signal your liver releases in response to growth hormone) levels haven't increased meaningfully on lower doses
  • Your physician recommends the standard FDA-approved dose

Go down if…

  • You experience significant joint pain or swelling
  • Blood glucose levels rise substantially
  • Fluid retention becomes uncomfortable
  • Injection site reactions are severe or persistent

The ceiling: 2 mg once daily (the FDA-approved maximum dose)

Reconstitution, in plain words

How do I mix Tesamorelin?

Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Tesamorelin:

What you need

  • Tesamorelin powder vial
  • Sterile water for injection (provided with prescription products)
  • Insulin syringes (29-31 gauge, 1/2 inch needle)
  • Alcohol swabs
  • Sharps disposal container

A worked example

For Egrifta SV (2mg vial): Add the entire contents of the provided sterile water diluent (0.5 mL) to the vial. This gives you a concentration of 4 mg/mL. The prescribed dose of 1.4 mg = 0.35 mL to inject.

Working out your dose

At 4 mg/mL concentration: 1.4 mg dose = 0.35 mL (35 units on an insulin syringe). Always follow the specific reconstitution instructions for your particular product, as formulations differ.

Or let the calculator do it

Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Tesamorelin's recorded schedule.

TesamorelinOnce daily

How much peptide is in your bottle?

Look at the label on the vial. It’s the number next to the unit — like "5 mg". Labeled in IU? Switch the unit to IU.

Type a number to continue.
0

Injection sites & technique

Where do I inject Tesamorelin?

The best spots

  • Abdomen (2 inches away from belly button), the most common site
  • Front or outer thigh
  • Rotate sites to prevent lipodystrophy (lumps or dents in fat) at injection spots

How to do it, step by step

  • Wash hands thoroughly with soap and water
  • Clean the injection site with an alcohol swab and let dry completely
  • Pinch a fold of skin between thumb and forefinger
  • Insert needle at a 45 to 90-degree angle (90 for more tissue, 45 for lean individuals)
  • Inject slowly and steadily over 5-10 seconds
  • Wait 5 seconds before withdrawing the needle
  • Do not rub the injection site afterward

Injection just under the skin into fatty tissue (subcutaneous (under the skin))—this is the only approved way to give it

Timing

When do I take Tesamorelin?

Best time of day

Inject in the morning on an empty stomach, at least 30 minutes before eating. This aligns with your natural cortisol (the stress hormone) awakening response and may optimize growth hormone release patterns.

With or without food?

Do NOT inject with food. Tesamorelin should be given on an empty stomach for optimal absorption. Wait at least 30 minutes after injection before eating breakfast.

Taking it with other peptides

If using with other growth hormone secretagogues (compounds that prompt your body to release growth hormone), separate injections by several hours. Some practitioners alternate between tesamorelin and other GHRH peptides rather than using them the same day. Never combine with exogenous (supplied from outside the body) GH—choose one or the other 16.

The honest list

What side effects could Tesamorelin cause?

Common — usually mild

These show up most often. They usually fade as your body adjusts.

Less common

Worth knowing about, but most people never see these.

Serious — stop and get medical help

Rare, but if any of these happen, stop and contact a medical professional.

Week by week

What should I expect from Tesamorelin, and when?

  1. Weeks 1-2

    You might notice
    What's normal
    • Mild injection site redness or itching that resolves in 1-2 days
    • Slight puffiness in extremities, especially in the morning
    • Initial adjustment period discomfort
    What's next
    • Continue with daily injections at consistent times
    • Track any side effects to discuss with your doctor
    • Side effects typically improve as your body adjusts

  2. Weeks 3-8

    You might notice
    What's normal
    • Settling into the routine with manageable side effects
    • Subtle changes in how your midsection looks or feels
    • Better tolerance than the first couple weeks
    What's next
    • Continue consistent daily dosing
    • Most practitioners recommend imaging (CT or MRI) at baseline and 12-26 weeks
    • Monitor blood glucose at regular intervals

  3. Weeks 12-26

    You might notice
    What's normal
    What's next

  4. Weeks 26-52 and beyond

    You might notice
    What's normal
    What's next
    • Many patients continue indefinitely for maintenance
    • Regular monitoring of IGF-1 (a growth signal your liver releases in response to growth hormone) and glucose recommended
    • Reassess periodically with your healthcare provider

How to tell it's actually working

Body Composition

Metabolic Markers

Subjective Well-Being

Not seeing anything? The usual reasons

Is it right for you?

Who should avoid Tesamorelin?

Do not use it if…

  • You have active cancer or a history of cancer, because growth hormone can potentially stimulate tumor growth
  • You have pituitary (the master hormone gland at the base of the brain) problems from surgery, radiation, or tumors affecting the link between the hypothalamus (the brain region that runs your hormone system) and pituitary (the brain's hormone control center)
  • You are pregnant or planning to become pregnant
  • You have a known allergy to tesamorelin or mannitol (a stabilizing ingredient)
  • You have uncontrolled diabetes, because tesamorelin can worsen how your body handles sugar

Be extra careful if…

  • You have pre-diabetes or impaired glucose tolerance—monitor blood sugar closely
  • You take medications that affect blood sugar like insulin or oral diabetes drugs
  • You have a history of carpal tunnel syndrome—GH elevation can worsen symptoms
  • You have fluid retention issues or heart problems—edema (fluid retention and swelling) can occur
  • You take glucocorticoids (steroids)—they may reduce tesamorelin's effectiveness
  • You're over 65—less clinical data exists for elderly patients

When to stop

Tesamorelin is an FDA-approved prescription medication that should only be used under physician supervision. Never start, stop, or adjust your dose without consulting your prescribing healthcare provider. This information is educational and does not constitute medical advice.

What it mixes badly (and well) with

Medications

  • Avoid
    Insulin

    Tesamorelin can raise blood glucose (sugar), so insulin doses may need adjusting. Monitor closely.

  • Avoid
    Oral diabetes medications

    Doses may need adjusting because tesamorelin affects how the body handles glucose. Work with your endocrinologist (hormone specialist).

  • Check first
    Glucocorticoids (prednisone, etc.)

    Steroids may reduce tesamorelin's effectiveness and work against its fat-reduction benefits.

  • Avoid
    Growth hormone

    Do not combine. Using both would be redundant and could cause excessive growth hormone effects.

Other peptides

  • OK together
    CJC-1295

    Works in a similar way (the GHRH pathway, the brain's growth hormone starter signal). Can be used together but may be redundant. Some practitioners alternate rather than combine.

  • OK together
    Ipamorelin

    Works on a different receptor (a GHRP, growth hormone-releasing peptide, receptor). Can complement tesamorelin for greater growth hormone release. Use at different times of day.

  • Check first
    Sermorelin

    Works in a very similar way (also a GHRH analog, a copy of the brain's growth hormone starter signal). Generally not used together—choose one or the other.

  • OK together
    BPC-157

    Works in a completely different way (a healing peptide). Safe to use together if addressing different goals.

Supplements

  • OK together
    Arginine

    May add to growth hormone release. Generally safe but probably unnecessary with tesamorelin.

  • Check first
    Glucose disposal agents (berberine, etc.)

    May help offset tesamorelin's blood-sugar-raising effect. Discuss with your doctor.

  • OK together
    Fish oil

    Safe to combine. May add to the triglyceride-lowering (blood fat-lowering) effect of tesamorelin.

  • OK together
    Chromium

    Safe. May help with blood sugar control.

Who it tends to suit

People with Stubborn Visceral Fat

If you carry your weight around your midsection—the deep belly fat that wraps around your organs—tesamorelin is specifically designed for you. Unlike weight loss drugs, it targets visceral fat while preserving the normal subcutaneous (under the skin) fat that's healthy to have 5.

People with HIV and Abnormal Fat Build-Up (lipodystrophy)

Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy (lumpy or dented fat under the skin at injection sites): abnormal fat buildup in the belly that HIV medications can cause 6. It's the only treatment proven to help this condition, reducing both the physical and emotional burden 15.

Those Concerned About Metabolic Health

Visceral fat (the deep belly fat around your organs) isn't just cosmetic. It's metabolically dangerous and linked to heart disease, diabetes, and inflammation 1012. By reducing visceral fat, tesamorelin also improves triglycerides (blood fats) and cholesterol ratios, and may help protect your liver from fatty liver disease 124.

Adults Wanting a Natural Growth Hormone (GH) Boost

Unlike synthetic growth hormone injections, tesamorelin works WITH your body's natural systems. It tells your pituitary (the brain's hormone gland) to release more of YOUR OWN growth hormone. This keeps normal feedback loops in place and lowers the risks of growth hormone levels that are higher than the body would ever make 10.

The safety picture overall

Tesamorelin has a strong safety profile backed by FDA approval and multiple large Phase 3 clinical trials involving over 800 patients 16. The most common issues are injection site reactions and the typical side effects of elevated growth hormone (joint pain, fluid retention) 6. Glucose metabolism should be monitored as some patients experience increased blood sugar 6. Long-term cardiovascular safety data is still being collected, which is why the FDA recommends reassessing treatment if visceral fat doesn't reduce 6.

Safety data comes from well-designed, placebo-controlled Phase 3 trials published in peer-reviewed journals and reviewed by the FDA 16. Studies extended up to 52 weeks with safety monitoring 1. This represents some of the strongest evidence available for any peptide therapy.

Keeping it good

How do I store Tesamorelin?

Before mixing (powder)

Store powder in refrigerator at 36-46°F (2-8°C). Keep in original carton to protect from light. Do not freeze. Check expiration date on package—stable until that date if properly stored.

After mixing (liquid)

Refrigerate reconstituted solution at 36-46°F (2-8°C). Use within 14 days for Egrifta SV (original Egrifta had shorter stability). Never freeze reconstituted solution. If solution becomes cloudy or contains particles, do not use.

Signs it has gone bad

  • Cloudy or hazy appearance (should be clear and colorless)
  • Visible particles or floaters
  • Any color change from clear/colorless
  • Solution that doesn't dissolve completely during reconstitution

Not our opinion — the published record

What the studies actually found about Tesamorelin

2010

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials

In this combined analysis of over 800 HIV patients, tesamorelin reduced visceral fat (deep belly fat) by an average of 15.4% compared to placebo at 26 weeks. The reduction was maintained at 52 weeks in those who continued treatment. It also improved triglycerides (blood fats) by 12% and significantly improved how patients felt about their belly appearance.

Falutz J, Mamputu JC, Potvin D, et al.

2012

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin

Patients who achieved at least 8% reduction in visceral fat (called 'responders') experienced significantly greater improvements in triglycerides, glucose control, and adiponectin levels (adiponectin is a hormone linked to better blood sugar handling) compared to non-responders. This shows that the metabolic benefits match how much visceral fat you lose.

Stanley TL, Falutz J, Marsolais C, et al.

2012

Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults

In a 20-week trial with 152 adults (some with mild cognitive impairment, early memory and thinking problems), tesamorelin improved executive function (planning and decision-making skills) and showed a trend toward better verbal memory. IGF-1 levels (a growth signal) increased 117% and body fat decreased 7.4%. This suggests tesamorelin may have brain health benefits beyond just fat reduction.

Baker LD, Barsness SM, Borson S, et al.

2011

Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy

This comprehensive review confirmed tesamorelin's effectiveness and safety profile. It noted that while visceral fat falls significantly, subcutaneous fat (fat under the skin) stays stable. This is an important difference because subcutaneous fat is metabolically healthier. Side effects were manageable and serious events occurred in less than 4% of patients.

Dhillon S

2010

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension

In this 12-month trial of 404 HIV-infected patients, visceral fat fell 10.9% on tesamorelin versus 0.6% on placebo over the first 6 months. It was about 18% below baseline in patients who continued the drug for 12 months. Patients switched (re-randomized) from tesamorelin to placebo quickly lost the visceral fat reduction they had gained. No change in glucose measures was observed.

Falutz J, Potvin D, Mamputu JC, et al.

2007

Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue

Adding a trans-3-hexenoyl group (a small chemical attachment) to the first amino acid of GHRH(1-44) made the peptide resistant to breakdown by dipeptidyl aminopeptidase-IV (an enzyme that chops up peptides). This slowed its breakdown in rat, dog and human plasma (the liquid part of blood) and kept it in circulation longer. The modified peptide still raised growth hormone and IGF-1 in pigs, rats and dogs. The apparent elimination half-life (the time for half of it to leave the body) in dogs was 21 to 45 minutes.

Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P

2025

Growth hormone-releasing hormone receptor (GHRH-R) and its signaling

This review describes how GHRH (growth hormone-releasing hormone) attaches to the GHRH receptor on the pituitary gland. This receptor is a G protein-coupled receptor (a type of cell-surface receptor) found mainly on somatotroph cells (growth-hormone-making cells). Activating the receptor raises intracellular cAMP (a chemical messenger inside the cell). The resulting signals add phosphate groups to CREB (a protein that switches genes on), which together with its helper proteins p300 and CREB-binding protein increases growth hormone gene activity (transcription).

Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV

If this isn't the right fit

What people use instead of Tesamorelin

Reducing belly fat through other peptides

  • Sermorelin
  • CJC-1295 + Ipamorelin
  • AOD-9604

Weight loss (general)

  • Semaglutide
  • Tirzepatide
  • Lifestyle modifications

Increasing growth hormone naturally

  • GHRP-6
  • Ipamorelin
  • Sermorelin
  • MK-677

Your questions

Tesamorelin FAQ

Will tesamorelin help me lose weight?

Tesamorelin is 'weight neutral'—you probably won't see the number on the scale change much 11. What changes is your body composition: visceral fat goes down significantly while other tissues stay stable 15. You might drop a pants size without losing pounds because visceral fat is being replaced by nothing (not muscle). If overall weight loss is your goal, consider GLP-1 (a gut hormone that tells your brain you're full) medications like semaglutide instead.

How is tesamorelin different from growth hormone injections?

Big difference! Growth hormone injections give you growth hormone from outside, which can shut down your own production and push levels higher than the body would ever make 1416. Tesamorelin tells your pituitary (the brain's hormone gland) to release more of YOUR OWN growth hormone, keeping natural feedback loops and the natural on-and-off release pattern 10. It's like turning up the volume on your natural system rather than replacing it with a synthetic one.

Why is it only FDA-approved for HIV patients?

HIV-associated lipodystrophy (abnormal fat distribution from antiretroviral drugs) was the specific condition Theratechnologies targeted for approval because there was no treatment for it 6. The FDA approval process is disease-specific. However, the mechanism works in anyone with excess visceral fat—that's why physicians prescribe it off-label for non-HIV patients with similar issues 3.

What happens when I stop taking tesamorelin?

Unfortunately, the visceral fat comes back. Clinical trials showed that patients who switched from tesamorelin to placebo regained their visceral fat within 26 weeks 57. This means tesamorelin is typically a long-term or indefinite treatment if you want to maintain the benefits. Think of it like blood pressure medication—it works while you take it.

Will tesamorelin affect my blood sugar?

It can, which is why monitoring is important. Growth hormone works against insulin, so fasting glucose and HbA1c (your average blood sugar over about 3 months) can rise in some patients 6. Clinical trials showed that most patients had only mild changes that didn't reach clinical significance. But if you have pre-diabetes or diabetes, you need closer monitoring and possible medication changes 17.

Can I use tesamorelin for bodybuilding?

While tesamorelin does increase GH and IGF-1 (a growth signal your liver releases in response to growth hormone), it's not ideal for bodybuilding purposes 3. It's specifically designed to reduce visceral fat, not build muscle. The GH increase is more modest than what bodybuilders typically seek with other secretagogues (compounds that prompt a hormone's release) or direct GH. If muscle growth is your primary goal, other peptide combinations might be more appropriate.

How long until I see results?

Most visible and measurable changes occur between weeks 12-26 1. You might notice subtle changes earlier (clothes fitting differently, less bloating), but the significant 15-18% reduction in visceral fat that clinical trials demonstrated takes several months of consistent daily use 1. Patience and consistency are key.

Is tesamorelin safe to use long-term?

Clinical trials studied tesamorelin for up to 52 weeks and found it well-tolerated with manageable side effects 15. Many patients use it indefinitely since stopping causes visceral fat to return 57. However, long-term cardiovascular safety data is still being collected, which is why the FDA recommends reassessing if you don't see visceral fat reduction 6. Regular monitoring of IGF-1 (a growth signal your liver releases in response to growth hormone) and glucose is recommended for extended use 6.

16 sources

References

Every numbered marker on this page points to one of these. Same sources, same numbering as the Tesamorelin research profile on Peptide Initiative.

  1. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trialsFalutz J, Mamputu JC, Potvin D, et al. · 2010
  2. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelinStanley TL, Falutz J, Marsolais C, et al. · 2012
  3. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adultsBaker LD, Barsness SM, Borson S, et al. · 2012
  4. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trialStanley TL, Fourman LT, Feldpausch MN, et al. · 2019
  5. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophyDhillon S · 2011
  6. EGRIFTA SV (tesamorelin for injection) Prescribing InformationTheratechnologies Inc. / U.S. FDA · 2019
  7. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionFalutz J, Potvin D, Mamputu JC, et al. · 2010
  8. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogueFerdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P · 2007
  9. Growth hormone-releasing hormone receptor (GHRH-R) and its signalingHalmos G, Szabo Z, Dobos N, Juhasz E, Schally AV · 2025
  10. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studiesStanley TL, Grinspoon SK · 2015
  11. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trialMakimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, Grinspoon SK · 2012
  12. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statementNeeland IJ, Ross R, Despres JP, et al. · 2019
  13. The enigmatic role of growth hormone in age-related diseases, cognition, and longevityColon G, Saccon T, Schneider A, et al. · 2019
  14. Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacementReed ML, Merriam GR, Kargi AY · 2013
  15. Human growth hormone receptor (GHR) expression in obesity: I. GHR mRNA expression in omental and subcutaneous adipose tissues of obese womenErman A, Veilleux A, Tchernof A, Goodyer CG · 2011
  16. Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal menHashimoto Y, Kamioka T, Hosaka M, Mabuchi K, Mizuchi A, Shimazaki Y, Tsunoo M, Tanaka T · 2000

Want the deep science?

Read the full Tesamorelin research profile

Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.

Open the research profile

More growth hormone guides

This guide is education, not medical advice. Tesamorelin is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.